Uniform Bio Inc.
Summary
Uniform Bio Inc. raised $65.0M in a Regulation D private placement on June 2, 2026, with backing from top-tier venture firms Flagship Pioneering and ARCH Venture Partners. The filing is an initial Form D, indicating a fresh capital raise in the technology venture sector. This substantial amount for a private company signals strong investor confidence and potential for significant growth.
See which stocks are affected
Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.
Already have an account? Log in
Full Analysis
Executive Summary
Uniform Bio Inc. raised $65.0M in a Regulation D private placement on June 2, 2026, with backing from top-tier venture firms Flagship Pioneering and ARCH Venture Partners. The filing is an initial Form D, indicating a fresh capital raise in the technology venture sector. This substantial amount for a private company signals strong investor confidence and potential for significant growth.
Investor Edge
Sophisticated investors should monitor for a subsequent Form D/A (amendment) which could reveal a larger round or changed terms, and watch for any public disclosures of partnerships or clinical milestones that often follow such raises.
Sector capital positioning
The $65.0M raise in Technology Venture underscores robust capital flow into deep-tech or biotech-adjacent startups, likely targeting high-risk, high-reward innovations. The involvement of Flagship and ARCH suggests a focus on platform technologies or novel therapeutics.
Convergence Signals
No public signals (patents, contracts, legislation) are evident from the filing data. The absence of a ticker and the private nature of the company limit convergence insights.
Key Takeaways
- Uniform Bio Inc. raised $65.0M in a private placement, a significant sum for a pre-IPO company.
- Backed by Flagship Pioneering and ARCH Venture Partners, indicating high-caliber institutional support.
- Initial Form D suggests this is a new raise, not an amendment, implying fresh capital injection.
Risk Indicators & Flags
No red flags identified: the filing is an initial Form D (not an amendment), the amount is consistent with a large venture round, and the sector is typical for such raises. However, the state is listed as 'Unknown,' which may indicate incomplete disclosure or a non-U.S. entity, warranting further due diligence.
Verification & References
Verify filing details via SEC EDGAR using accession number 000213678126000001. Confirm company name (Uniform Bio Inc.), CIK (0002136781), and capital amount ($65.0M) directly from the Form D filing.
Connected Signals
Matched on shared policy language across AI analyses, with ticker & timing weight
Dare Bioscience, Inc.
Anika Therapeutics, Inc.
Matthias Therapeutics, LLC
DEF 14A - Outlook Therapeutics, Inc.
Related Presidential Actions
Executive orders & memoranda affecting the same sectors or companies
Streamlining Access to Government Services Through America.gov
The executive order directs the General Services Administration to create America.gov, a unified digital portal for federal services, integrating Login.gov for authentication and requiring agencies to expose their digital services via APIs. It also mandates the use of AI (referred to as 'super intelligence') with transparency safeguards, while preserving existing service channels and excluding tax and defense/intelligence services.
Enhancing Program Integrity and Integrity and Interagency Coordination in the Administration of the H-1B Nonimmigrant Visa Program
This executive order directs the Secretaries of State, Labor, and Homeland Security to coordinate with Commerce, Education, and the SBA when processing H-1B petitions, and requires them to consider whether the employer has engaged in layoffs of similarly situated U.S. workers within the past year. It also orders the Labor Department to review past labor condition applications for potential enforcement actions against sponsoring employers, effectively tightening scrutiny on H-1B usage, especially by outsourcing firms.
Restriction on Entry of Certain Nonimmigrant Workers
This proclamation extends for an additional 12 months the existing restriction on entry of H-1B nonimmigrant workers, which requires a $100,000 payment per petition (with limited exceptions) and is supported by a DHS weighted selection process that prioritizes higher-skilled, higher-paid workers. The action continues to target IT staffing and outsourcing firms that have abused the program, and it maintains the requirement for ongoing rulemakings by DHS and DOL to further reform wage protections and program integrity.
Free — no credit card
Get the next market-moving signal before the news does
HillSignal scores every Congressional bill, federal contract, and insider filing for market impact and emails you the high-conviction ones — free, no credit card.
Weekly digest — the congressional activity that actually moved markets that week, in plain English. Free, one email.
Free forever plan · No credit card · Unsubscribe in one click
Want the live terminal too? Create a free account →